参考文献/References:
[1] Frew IJ, MochH. Aclearer view ofthe molecular complexity of clearcellrenal cell carcinoma[J].Annu RevPathol,2015,10(1): 263-289.
[2] McguireS.Worldcancerreport2014.Geneva,Switzerland:World Health Organization, international agency for research on cancer, WHOpress,2015[J].AdvNutr,2016,7(2):418-419.
[3] Qu Y, Gu C, Wang H, et al. Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic chinese population[J].SciRep,2016,6:21677.
[4] SrigleyJR,DelahuntB,EbleJN,etal.Theinternationalsocietyof urological pathology (ISUP) Vancouver classification of renal neoplasia[J].AmJSurgPathol,2013,37(10):1469-1489.
[5] Eble JN, Bonsib SM. Extensively cystic renal neoplasms: cystic nephroma, cystic partially differentiated nephroblastoma, multilocular cystic renal cell carcinoma, and cystic hamartoma of renalpelvis[J].SeminDiagnPathol,1998,15(1):2-20.
[6] Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical studyof 105 tumors[J].ModPathol,1997,10(6):537-544.
[7] Jiang F, Richter J, SchramlP, et al. Chromosomalimbalances in papillary renal cell carcinoma: genetic differences between histologicalsubtypes[J].AmJPathol,1998,153(5):1467-1473.
[8] Linehan WM, Spellman PT, Ricketts CJ, et al. Comprehensive molecularcharacterizationofpapillaryrenal-cellcarcinoma [J].N EnglJMed,2016,374(2):135-145.
[9] LohseCM,GuptaS,ChevilleJC.Outcomeprediction forpatients with renal cell carcinoma [J]. Semin Diagn Pathol, 2015, 32(2): 172-183.
[10] Doros LA, Rossi CT, Yang J, et al. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma[J].ModPathol,2014,27(9):1267-1280.
[11] Haq R, Fisher DE. Biology and clinical relevance of the micropthalmia familyoftranscription factors in human cancer[J]. JClinOncol,2011,29(25):3474-3482.
[12]甘卫东 ,曹翔 ,郭宏骞 . MiTF家族相关性肾癌的研究进展 [J/CD].中华腔镜泌尿外科杂志:电子版,2014,8(6):393-396.
[13] Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomataandpapillaryrenalcellcancer [J].NatGenet,2002, 30(4):406-410.
[14] Merino MJ, Torres-Cabala C, Pinto P, et al. The morphologic spectrumofkidneytumorsinhereditaryleiomyomatosisandrenal cellcarcinoma (HLRCC)syndrome [J].AmJSurgPathol,2007, 31(10):1578-1585.
[15] Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity:aclinicopathologicseriesof36tumorsfrom27patients[J]. AmJSurgPathol,2014,38(12):1588-1602.
[16] Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutationsandfamilialrenalcellcarcinoma[J].JNatlCancerInst, 2008,100(17):1260-1262.
[17] ZhouM,YangXJ,LopezJI,etal.Renaltubulocysticcarcinomais closely related to papillary renal cell carcinoma: implications for pathologicclassification [J]. AmJSurgPathol,2009,33(12): 1840-1849.
[18] AminMB,MaclennanGT,GuptaR,etal.Tubulocysticcarcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma [J]. Am J Surg Pathol,2009,33(3):384-392.
[19] Yang XJ, Zhou M, Hes O, et al. Tubulocystic carcinoma of the kidney:clinicopathologicandmolecularcharacterization[J].AmJ SurgPathol,2008,32(2):177-187.
[20] Azoulay S, VieillefondA, ParafF, et al. Tubulocystic carcinoma of the kidney: a new entity among renal tumors [J]. Virchows Arch,2007,451(5):905-909.
[21] Tickoo SK, Deperalta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia[J]. AmJSurgPathol,2006,30(2):141-153.
[22] Rohan SM, Xiao Y, Liang Y, et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factorpathway-relatedproteins [J].ModPathol,2011,24(9): 1207-1220.
[23] ZhouH,ZhengS,TruongLD,etal.Clearcellpapillaryrenal cell carcinomaisthefourthmostcommonhistologictypeofrenalcell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma[J].HumPathol,2014,45(1):59-64.
[24] Medeiros LJ, Palmedo G, Krigman HR, et al. Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity [J]. Am J Surg Pathol, 1999, 23 (7):772-780.
[25] ArganiP,Laé M,BallardET,etal.Translocationcarcinomasof the kidney after chemotherapy in childhood [J]. J Clin Oncol, 2006,24(10):1529-1534.
[26] JungSJ,ChungJI,ParkSH,etal.Thyroidfollicularcarcinoma-like tumor of kidney: a case report with morphologic, immunohistochemical,andgeneticanalysis[J].Am JSurg Pathol, 2006,30(3):411-415.
[27] AminMB,GuptaR,OndrejH,etal.Primarythyroid-likefollicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm [J]. Am JSurg Pathol, 2009,33(3):393-400.
[28] Berens S, Vogt P, Alkadhi H, et al. Thyroid-like follicular carcinoma of the kidney: a separate tumor entity?[J]. Pathologe, 2014,35(1):83-87.
[29] SukovWR, Hodge JC, Lohse CM, et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcomeinalargeseriesofconsecutivelytreatedpatients[J].Mod Pathol,2012,25(11):1516-1525.
[30] Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method [J]. Cancer, 2012, 118(18): 4427-4436.
[31] DebelenkoLV,RaimondiSC,DawN,et al.Renalcellcarcinoma with novel VCL-ALK fusion: new representative of ALK-associatedtumorspectrum [J]. ModPathol, 2011,24(3): 430-442.
[32] DemlKF, Schildhaus HU, CompératE, et al. Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor:two variants of a morphologic, immunohistochemical, and genetic distinctentityofrenalcellcarcinoma[J].Am JSurgPathol,2015, 39(7):889-901.
[33] HakimiAA,TickooSK, Jacobsen A, et al. TCEB1-mutated renal cell carcinoma: adistinct genomic and morphological subtype[J]. ModPathol,2015,28(6):845-853.
[34] Yang P, Cornejo KM, SadowPM, et al. Renal cell carcinoma in tuberous sclerosis complex [J]. Am J Surg Pathol, 2014, 38(7): 895-909.
[35] DelahuntB,Sika-PaotonuD,BethwaitePB,etal.Fuhrmangrading isnotappropriateforchromophoberenalcellcarcinoma [J].AmJ SurgPathol,2007,31(6):957-960.
[36] Delahunt B, Cheville JC, Martignoni G, et al. The international society ofurological pathology (ISUP) grading systemfor renal cell carcinoma and other prognostic parameters [J]. Am J Surg Pathol,2013,37(10):1490-1504.
[37] Moch H, Montironi R, Lopez-Beltran A, et al. Oncotargets in differentrenalcancersubtypes[J].CurrDrugTargets,2015,16(2): 125-135.
[38] GerlingerM,RowanAJ,HorswellS,etal.Intratumorheterogeneity andbranchedevolutionrevealedbymultiregionsequencing [J].N EnglJMed,2012,366(10):883-892.
[39] GerstungM,BeiselC,Rechsteiner M,etal.Reliabledetection of subclonalsingle-nucleotidevariantsintumourcellpopulations[J]. NatCommun,2012,3:811.
[40] Tan PH, Cheng L, Rioux-Leclercq N, et al. Renal tumors: diagnosticandprognosticbiomarkers[J].AmJSurgPathol,2013, 37(10):1518-1531.
[41] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma[J]. Nature,2013,499(7456):43-49.
[42] Finley DS, Shuch B, Said JW, et al. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renalcellcarcinoma[J].JUrol,2011,186(6):2168-2174.
[43] Paner GP, Amin MB, Alvarado-Cabrero I, et al. A novel tumor gradingschemeforchromophoberenalcellcarcinoma:prognostic utilityandcomparisonwithFuhrmannucleargrade[J].Am JSurg Pathol,2010,34(9):1233-1240.
[44] ChevilleJC,LohseCM,SukovWR,etal.Chromophoberenalcell carcinoma:theimpactoftumorgradeonoutcome [J].AmJSurg Pathol,2012,36(6):851-856.
[45] Amin MB, Paner GP, Alvarado-Cabrero I, et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145cases[J].AmJSurgPathol,2008,32(12):1822-1834.